Potential Applications of RNase P Ribozyme Against Hepatitis B Virus

Area of Science:

• Molecular Biology
• RNA Therapeutics
• Hepatology

Background:

• Hepatitis B virus (HBV) infection affects over 250 million people globally, leading to cirrhosis and liver cancer.
• Current treatments for chronic HBV infection are insufficient for complete viral elimination.
• Nucleic acid-based gene-targeting molecules, including ribozymes, are emerging as potential therapeutic agents.

Purpose of the Study:

• To review recent advancements in utilizing RNase P ribozymes for inhibiting HBV.
• To discuss the potential of engineered RNase P ribozymes in therapeutic applications against HBV infection.

Main Methods:

• Engineering of M1 RNA from Escherichia coli RNase P into M1GS ribozymes by linking it to a guide sequence.
• In vitro selection process to enhance M1GS ribozyme activity, improving cleavage efficiency and substrate affinity.
• Demonstration of RNase P ribozyme efficacy in inhibiting HBV gene expression and replication in human cells.

Main Results:

• Engineered M1GS ribozymes exhibit sequence-specific endonuclease activity, degrading target mRNA.
• Mutations introduced via in vitro selection led to ribozyme variants with enhanced catalytic activity and substrate binding.
• RNase P ribozymes effectively suppressed HBV gene expression and replication in cellular models.

Conclusions:

• RNase P ribozymes represent a promising nucleic acid-based strategy for gene interference against HBV.
• Engineered ribozymes demonstrate significant potential for therapeutic development against chronic HBV infection and its sequelae.
• Further development of these engineered ribozymes could lead to novel treatments for HBV-associated liver diseases.